Abstract: Breast cancer is one of the most prevalent malignancies in the world, and triple-negative breast cancer (TNBC) accounts for 10%–20% of invasive breast cancers. Treatment options for TNBC are relatively scarce and prognosis is usually poor. Thus, finding new targets for precise treatment to improve prognosis is necessary. Trophoblast cell surface antigen 2 (Trop2) is highly expressed in TNBC and many other malignant tumors. Trop2 plays an important role in tumor cell proliferation, adhesion, invasion, and metastasis through cell surface receptor signaling. Antibody-drug conjugates (ADC) targeting Trop2 offer promise in clinical application. This article discusses clinical research progress for the clinical application of Trop2 targeting ADC to treat TNBC and improve patient prognosis.